Risk factors for vulvovaginal candidiasis: A case-control study among university students

Epidemiology

Volumn 7, Issue 2, 1996, Pages 182-187

  Geiger, Ann M ^a   Foxman, Betsy ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

gender; minority groups; oral contraceptives; risk factors; sex behavior; spermatocidal agents; vulvovaginal candidiasis

Indexed keywords

ORAL CONTRACEPTIVE AGENT; SPERMICIDAL AGENT;

ADULT; ARTICLE; CANDIDA ALBICANS; CASE CONTROL STUDY; COLLEGE STUDENT; CONTROLLED STUDY; FEMALE; FUNGUS CULTURE; HUMAN; MAJOR CLINICAL STUDY; PERSONAL HYGIENE; PRIORITY JOURNAL; RACE; RISK FACTOR; SEXUAL BEHAVIOR; VAGINA CANDIDIASIS;

EID: 0030041482     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-199603000-00013     Document Type: Article

References (31)

1. McCormack WM Jr, Zinner SH, McCormack WM. The incidence of genitourinary infections in a cohort of healthy women. Sex Transm Dis 1994;21:63-64.
2. Reed BD, Slattery ML, French TK. The association between dietary intake and reported history of Candida vulvovaginitis. J Fam Pract 1989;29:509-515.
3. Berg AO, Heidrich FE, Fihn SD, Bergman JJ, Wood RW, Stamm WE, Holmes KK. Establishing the cause of genitourinary symptoms in women in a family practice: comparison of clinical examination and comprehensive microbiology. JAMA 1984;251:620-625.
4. Larsen B. Microbiology of the female genital tract. In: Pastorek JG, ed. Obstetric and Gynecologic Infectious Disease. New York: Raven Press, 1994;11-25.
5. Vartivarian S, Smith CB. Pathogenesis, host resistance, and predisposing factors. In: Bodey GP, ed. Candidiasis: Pathogenesis, Diagnosis and Treatment. New York: Raven Press, 1993;59-84.
6. Reed BD. Risk factors for Candida vulvovaginitis. Obstet Gynecol Surv 1992;47:551-560.
7. Foxman B. The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health 1990;80:329-331.
8. Warren NG, Shadomy HJ. Yeasts of medical importance. In: Balows A, ed. Manual of Clinical Microbiology. Washington DC: American Society for Microbiology, 1991;620-624.
9. Breslow NE, Day NE. Statistical Methods in Cancer Research. vol. 1. The Analysis of Case-Control Studies. IARC Scientific Pub. No. 32. Lyon: International Agency for Research on Cancer, 1980.
10. EGRET Software Program, Version 0.26.6. Seattle: Statistics and Epidemiology Research Corporation and Cytel Software Corporation, 1991.
11. SAS Institute. Computer software, Version 6.08. Cary, NC: SAS Institute, 1989.
12. University of Michigan. Minority Report No. 836. Ann Arbor: University of Michigan Office of the Registrar, 1993.
13. Hart G. Factors associated with trichomoniasis, candidiasis and bacterial vaginosis. Int J STD AIDS 1993;4:21-25.
14. Markos AR, Wade AA, Walzman M. Oral sex and recurrent vulvo-vaginal candidiasis. Genitourin Med 1992;68:61-62.
15. Oates JK. Recurrent vaginitis and oral sex. Lancet 1979;1:785.
16. White W, Spencer-Phillips PJ. Recurrent vaginitis and oral sex. Lancet 1979;1:621.
17. Odds FC. Candida and Candidosis. London: Baillière Tindall, 1988.
18. Davis BA. Salivary vulvitis. Obstet Gynecol 1971;37:238-240.
19. Ceruti M, Canestrelli M, Condemi V, Piantelli G, De Paolis P, Amone F, Tovagliari D. Methods of contraception and rates of genital infections. Clin Exp Obstet Gynecol 1994;21:119-123.
20. Davidson F, Oates JK. The pill does not cause 'thrush.' Br J Obstet Gynaecol 1985;92:1265-1266.
21. Roddy RE, Cordero M, Cordero C, Fortney JA. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 1993;4:165-170.
22. Cates W Jr, Stewart FH, Trussell J. Commentary: the quest for women's prophylactic methods - hopes vs science. Am J Public Health 1992;82:1479-1482.
23. Bird KD. The use of spermicide containing nonoxynol-9 in the prevention of HIV infection. AIDS 1991;5:791-796.
24. Niruthisard S, Roddy RE, Chutivongse S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis 1991;18:176-179.
25. Hooton TM, Roberts PL, Stamm WE. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis 1994;19:274-278.
26. Hooton TM, Hillier S, Johnson C, Roberts PL, Stamm WE. Escherichia coli bacteriuria and contraceptive method. JAMA 1991;265:64-69.
27. Rosenberg MJ, Rojanapithayakorn W, Feldblum PJ, Higgins JE. Effect of the contraceptive sponge on chlamydial infection, gonorrhea, and candidiasis: a comparative clinical trial. JAMA 1987;257:2308-2312.
28. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, Ruminjo I, Sajabi R, Kimata J, Fleming TR, Anzala A, Holton D, Plummet F. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992;268:477-482.
29. McGroarty JA, Soboh F, Bruce AW, Reid G. The spermicidal compound nonoxynol-9 increases adhesion of Candida species to human epithelial cells in vitro. Infect Immun 1990;58:2005-2007.
30. McCutchan JA, Ronald AR, Corey L, Handsfield HH. Evaluation of new anti-infective drugs for the treatment of vaginal infections. Clin Infect Dis 1992;15(suppl 1):S115-S122.
31. Geiger AM, Foxman B, Gillespie BW. Epidemiology of vulvovaginal candidiasis among university students. Am J Public Health 1995;85:1146-1148.